12,251 real negative results, null findings, and replication failures in Medicine. Search the index →
WASTE indexes published research — it does not host or republish full papers. Each entry is a metadata record compiled from open scholarly databases; the abstract is shown in full only where the paper is openly licensed, otherwise a short excerpt under fair use. Classifications are automated and approximate.
Sahebjam S, Bazer DA, Rhun EL et al. · 2026 · Neuro-oncology advances
Background Abemaciclib is a selective cyclin-dependent kinase 4 and 6 inhibitor that penetrates the blood-brain barrier, resulting in comparable concentrations in tissue and plasma. The primary objective of this nonrandomized Simon…
View details →Kim DW, Kim RD, Jimenez MM et al. · 2025 · The oncologist
Background Ramucirumab plus paclitaxel after progression on fluoropyrimidine/platinum in metastatic gastric (GA) and gastroesophageal junction adenocarcinoma (GEJC) has shown improvement in overall survival over paclitaxel alone. However,…
View details →Leelahawong P, Ketsuwan C · 2026 · Journal of clinical medicine
Background/Objectives : To evaluate whether adjunctive silodosin improves the stone-free rate (SFR) and clinical outcomes of extracorporeal shock wave lithotripsy (ESWL) for renal calculi. Methods : In this prospective randomised…
View details →Chibaudel B, Dourthe LM, André T et al. · 2026 · Signal transduction and targeted therapy
Managing unresectable metastatic colorectal cancer (mCRC) requires a comprehensive strategy. While chemotherapy, anti-angiogenic, and anti-epidermal growth factor receptor (EGFR) agents are available, strategy trials are needed to optimize…
View details →Wheless MC, Stockton S, Soares HP et al. · 2025 · The oncologist
Background Mutations in TP53 are common in gastroesophageal cancer and portend a poor prognosis. Tumor cells with TP53 mutations increasingly rely on ataxia-telangiectasia and Rad3-related (ATR) protein to respond to and repair DNA damage…
View details →Nagatani Y, Kiyota N, Yamazaki T et al. · 2026 · Japanese journal of clinical oncology
Background Salivary gland cancer (SGC) is rare and has various histological types. This rarity and heterogeneity have hindered elucidation of the therapeutic contribution of systemic therapy, including immune checkpoint inhibitors, to…
View details →Linardou H, Papadopoulou K, Korfiatis N et al. · 2025 · European journal of cancer (Oxford, England : 1990)
Background Extensive stage small cell lung cancer (ES-SCLC) has poor prognosis, and first-line chemo-immunotherapy is now the standard-of-care. We hypothesized that intercalated immunotherapy administration in-between chemotherapy cycles,…
View details →Sehgal K, Serritella A, Liu M et al. · 2025 · The Journal of clinical endocrinology and metabolism
Background There are limited therapeutic options for patients with recurrent/metastatic anaplastic thyroid carcinoma (ATC) and radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) refractory to multikinase inhibitors. This…
View details →Yazici Y, Tambiah JRS, Swearingen CJ et al. · 2025 · Clinical and experimental rheumatology
Objectives To determine the efficacy, safety, and tolerability of intraarticular (IA) lorecivivint (LOR) in the treatment of knee osteoarthritis (OA). Methods Patients with American College of Rheumatology criteria-defined knee OA,…
View details →Gratzke C, Özgüroğlu M, Peer A et al. · 2025 · Annals of oncology : official journal of the European Society for Medical Oncology
Background Despite treatment advances, most patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease progression to castration-resistant disease within 5 years. The placebo-controlled, double-blind, phase III…
View details →Guckenberger M, Opitz I, Dellaporta T et al. · 2025 · Lung cancer (Amsterdam, Netherlands)
Objective To evaluate the addition of immunotherapy and metastasis-directed stereotactic body radiotherapy (SBRT) to induction chemotherapy followed by definitive local therapy of the locoregional primary tumour in patients with…
View details →Lee JB, Choi SJ, Shim HS et al. · 2025 · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Introduction Treatment with adjuvant osimertinib for three years is the standard-of-care for resected stage IB to IIIA NSCLC harboring EGFR mutations. The role of neoadjuvant osimertinib in the perioperative setting is yet to be elucidated…
View details →Wills CA, Mohan S, Nabavizadeh A et al. · 2025 · Neuro-oncology advances
Background Novel treatments are needed for oligodendroglioma that has recurred following radiotherapy (RT) and chemotherapy. The cyclin D1-CDK4 axis is frequently dysregulated in oligodendroglioma. Abemaciclib is a selective CDK4/6…
View details →Cheng S, Kordbacheh T, Banyard A et al. · 2026 · Oncology research
Objectives The PACIFIC trial established the benefit of durvalumab following chemo-radiotherapy for stage III non-small cell lung cancer (NSCLC). However, the concurrent use of radiotherapy (RT) and durvalumab (PACIFIC-2 trial) showed no…
View details →Kaufman MR, Goldman HB, Chermansky CJ et al. · 2024 · Neurourology and urodynamics
Aims This study aimed to determine the efficacy and safety of iltamiocel investigational autologous muscle cell therapy in females with stress urinary incontinence (SUI). Methods Adult females were randomized 2:1 to iltamiocel (150 × 10 6…
View details →Shiraishi Y, Shimose T, Tobino K et al. · 2025 · Lung cancer (Amsterdam, Netherlands)
Background The current standard of care for advanced non-small cell lung cancer (NSCLC) without driver oncogenes is platinum-based chemotherapy together with immune checkpoint inhibition. However, most phase 3 trials of such combination…
View details →Lan H, Lu M, Li S et al. · 2026 · Frontiers in medicine
Objective High-quality bowel preparation is essential for accurate colonoscopy. Currently, linaclotide is used as an adjunctive agent supporting bowel preparation, but evidence for its combination with oral sulfate solution (OSS) remains…
View details →Damas OM, Leo M, Colina N et al. · 2025 · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Background & aims Diet may influence ulcerative colitis (UC), but its impact on medication response remains unclear. We examined whether two 5-day cycles of a low-calorie, plant-based (LC-PB), fasting-mimicking diet could improve UC…
View details →Masuishi T, Taniguchi H, Kotani D et al. · 2025 · ESMO open
Background Based on the reported antitumor effects of microtubule inhibitors in xenograft models of BRAF V600E mutant colorectal cancer, this multicenter phase II study aimed to evaluate the efficacy and safety of eribulin in patients with…
View details →Crown J, Eustace AJ, Collins DM et al. · 2025 · Acta oncologica (Stockholm, Sweden)
Background The docetaxel (T), carboplatin (C) and trastuzumab (H) regimen has been used in the (neo-) adjuvant treatment of HER2+ early stage breast cancer (ESBC). Lapatinib (L) a small molecule HER2 antagonist produces clinical responses…
View details →Zhang X, Yan J, Lei Q et al. · 2025 · International journal of radiation oncology, biology, physics
Purpose To investigate the efficacy of metastasis-directed therapy (MDT) when added to camrelizumab (Cam) in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC). Methods and materials We conducted a randomized,…
View details →Rhee H, Henderson LM, Bauer RN et al. · 2024 · Allergy
Background Tryptase, a mast cell protease, has been identified as a potential therapeutic target in managing patients with refractory asthma. We assessed the efficacy, safety, pharmacokinetics, and pharmacodynamics of MTPS9579A, an…
View details →Yoshioka H, Ishida T, Atagi S et al. · 2025 · Clinical lung cancer
Background We conducted a randomize phase II study to evaluate the efficacy and safety of topoisomerase II inhibitor amrubicin plus topoisomerase I inhibitor irinotecan (AI) compared with cisplatin plus irinotecan (PI) as first-line…
View details →Pressiani T, Balsano R, Giordano L et al. · 2024 · European journal of cancer (Oxford, England : 1990)
Introduction The prognosis of patients with advanced biliary tract cancer (BTC) is still poor, and new strategies improving patients' outcome are needed. In our trial we investigated safety and activity of nab-paclitaxel in combination…
View details →Cree BAC, Freedman MS, Gold M et al. · 2025 · Annals of neurology
Objective Elezanumab is a monoclonal antibody that binds repulsive guidance molecule a (RGMa), an inhibitor of central nervous system regeneration after inflammation or injury. The aim was to assess the safety and efficacy of elezanumab in…
View details →Lee JM, Miller A, Rose PG et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose We assessed the efficacy of anti-PD-L1 durvalumab in combination with olaparib and cediranib (DOC), compared with the standard-of-care chemotherapy (SOC) in patients with platinum-resistant ovarian cancer (PROC), who had prior…
View details →Gong J, Mita AC, Wei Z et al. · 2024 · JCO precision oncology
Purpose Despite fibroblast growth factor receptor ( FGFR ) inhibitors being approved in tumor types with select FGFR rearrangements or gene mutations, amplifications of FGFR represent the most common FGFR alteration across malignancies.…
View details →King B, Mesinkovska N, Senna M et al. · 2025 · Journal of the European Academy of Dermatology and Venereology : JEADV
Background Etrasimod, an oral, selective sphingosine 1-phosphate 1, 4 and 5 receptor modulator approved for the treatment of ulcerative colitis, has been studied in immune-mediated inflammatory diseases, including alopecia areata (AA).…
View details →Schulte B, Mohindra N, Milhem M et al. · 2021 · British journal of cancer
Background Pazopanib is active in refractory soft-tissue sarcoma (STS) and significantly prolongs PFS. Prior studies of combinations of metronomic topotecan with pazopanib have indicated preclinical evidence of response in patients with…
View details →Thavaneswaran S, Lin F, Espinoza D et al. · 2025 · NPJ precision oncology
This single-arm phase II trial (ACTRN12620000918921) evaluated the clinical activity of tremelimumab (10 mg/kg intravenously every 4 weeks for 6 cycles) in advanced cancers with a high tumour mutational burden (TMB), defined as TMB > 10…
View details →